Developer docs
API playgroundTry for free, no card

Search company profiles

Afon Technology

Full company profile

uuid00034je

Namestring
Afon Technology
Legal namestring
Afon Technology Ltd
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Afon Technology Ltd is a UK-based medical device company developing Glucowear™, a non-invasive, wrist-worn continuous blood glucose monitor. Founded by Dr Sabih Chaudhry and headquartered in Caldicot, Monmouthshire, Wales, the company has built a watch-format device that uses RF/microwave technology to analyse spectral variations in low-power radio signals reflected from the wrist to detect glucose levels, without skin penetration, needle insertion, or finger-prick calibration. The signal is transmitted via Bluetooth to a companion smartphone app for real-time display, and the device is designed for a two-year operational lifespan with minimal plastic and recyclable packaging. The underlying technology is protected by a granted patent (registered 2019) on the first real-time non-invasive blood glucose monitor.

The company is pre-commercial and is in clinical trials ahead of an anticipated UK launch in 2026. Manufacturing has been secured through a partnership with Sony UK Technology Centre announced in late 2025. Quality systems are BSI ISO 13485-certified (May 2023), and clinical evidence includes a proof-of-concept study in the Journal of Diabetes Science and Technology (April 2023, with an AI-accuracy pilot study published May 2024), ongoing NHS trials at the Joint Clinical Research Facility at Swansea University, and a real-world trial reporting approximately 75% overall accuracy with median ARD of 22% and mean ARD of 28% in Stage 2 testing.

Afon's business model centres on one-time, up-front hardware sales of the Glucowear device in the UK, with no subscription, membership, or replacement-sensor fees. The product is positioned both as a medical device for people with Type 1 and Type 2 diabetes and as a lifestyle accessory for prediabetics and metabolic-health-conscious non-diabetic consumers. To date, the company has been funded primarily through non-dilutive European Innovation Council grants (€2.5M in December 2022, €2.4M in May 2025 via Horizon Europe), a £600,000 confidential investor round in November 2022, and a $25,000 Junkosha Technology Innovator of the Year prize in April 2024; revenue has not yet been disclosed and the company is currently pre-revenue.

Short descriptiontext

Afon Technology is a UK-based medical device company developing Glucowear™, a wrist-worn, non-invasive continuous blood glucose monitor using RF/microwave technology. Pre-revenue, it is in clinical trials ahead of a planned 2026 UK launch for people with diabetes and metabolic-health consumers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCaldicot, United Kingdom
HQ citystring
Caldicot
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive glucose monitoring, continuous glucose monitor, wearable medical device, blood glucose sensor, diabetes monitoring technology
Industry2 codes
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Continuous Glucose Monitoring Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Hardware Device Sales
TypeHardware Sales
Description

Afon Technology sells Glucowear, a wearable medical device. The company plans to sell the device in the UK market with plans to begin selling in 2026. The device is described as having no additional running costs or membership fees, just an up-front purchase cost.

afontechnology.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Single device purchase model with no ongoing subscription fees
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Device available for up-front purchase only with no recurring membership or subscription fees. No additional running costs beyond the initial device purchase.

afontechnology.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Glucowear™
Description

The world's first non-invasive, real-time and continuous blood glucose sensor. A wrist-worn device that uses RF/microwave technology to monitor glucose levels without penetrating the skin, connecting via Bluetooth to smart devices and apps.

afontechnology.com
Core offering1 text field

Afon Technology develops Glucowear™, a wrist-worn wearable medical device that uses proprietary RF/microwave-based dial resonating sensor technology to continuously and non-invasively measure blood glucose levels in real time through spectral analysis of signals reflected from the wrist, without skin penetration or finger pricks. The device transmits readings via Bluetooth to a companion smartphone application, is designed for a two-year reusable lifespan, and is manufactured by Sony UK Technology Centre ahead of an anticipated 2026 UK commercial launch following NHS-backed clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ~75% overall accuracy in distinguishing between normal and elevated blood glucose levels in first real-world trial (March 2026)
+3 more records
Product overview1 text field

Afon Technology offers a single unified product, Glucowear™, which is the world's first non-invasive, real-time continuous blood glucose monitor. This wrist-worn device represents a paradigm shift from traditional invasive CGM systems that require needle sensors inserted under the skin. Glucowear uses ultra-low power microwave/RF signals to detect glucose levels and transmits data via Bluetooth to a companion smartphone app for real-time display. The device targets people with diabetes and prediabetes, as well as non-diabetic users interested in metabolic health monitoring. The company is currently in clinical trials ahead of an anticipated 2026 commercial launch in the UK, with manufacturing handled by Sony UK Technology Centre.

Product and service1 record
1Glucowear™
CategoryContinuous Glucose Monitoring Devices
Description

A wrist-worn, non-invasive, real-time continuous blood glucose monitor that uses proprietary RF/microwave-based dial resonating sensor technology to detect glucose levels through spectral analysis of signals reflected from the wrist, without skin penetration. The device transmits readings via Bluetooth to a companion smartphone app, is designed for a two-year reusable lifespan, works on all skin colours, and is intended for people with Type 1 or Type 2 diabetes as well as health-conscious non-diabetics seeking metabolic health insights. Manufacturing is handled by Sony UK Technology Centre ahead of an anticipated 2026 UK commercial launch following NHS clinical trials.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Sony UK Technology Centre
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-18
Description

Afon Technology partnered with Sony UK Technology Centre to manufacture Glucowear, its non-invasive continuous glucose monitoring device. The partnership was described as a pivotal moment in Afon's history, with Sony's manufacturing capabilities being used to scale production for the 2026 commercial launch in the UK. The agreement was finalized in late 2025 following an initial announcement in October 2025.

openaccessgovernment.org
2Journal of Diabetes Science and Technology
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-27
Description

Afon Technology published a clinical proof-of-concept study 'Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor' in the Journal of Diabetes Science and Technology in April 2023. The paper was co-authored with researchers from multiple institutions.

afontechnology.com
3Joint Clinical Research Facility (JCRF), Swansea University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Afon Technology is conducting clinical trials at the Joint Clinical Research Facility (JCRF) at Swansea University, where preliminary results were presented at ATTD Berlin 2023.

afontechnology.com
4Royal Liverpool Hospital
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr Sabih Chaudhry worked with the Royal Liverpool Hospital in 2013 to conduct the first trials on the non-invasive blood glucose monitoring technology, which was the foundational proof-of-concept work for Afon Technology.

healthcare-newsdesk.co.uk
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dexcom is the dominant player in continuous glucose monitoring (GCM), with the G6/G7 sensor lines used by hundreds of thousands of people with diabetes. Afon's Glucowear competes for the same end-user (continuous, real-time glucose data) but with a non-invasive watch-form device versus Dexcom's skin-penetrating patch.

TypeBroad incumbent
Description

Medtronic offers the Guardian CGM alongside its insulin pumps and closed-loop systems, targeting people with Type 1 diabetes. As a broad diabetes device incumbent it overlaps with Afon's target use case, though it does not currently address non-invasive or lifestyle segments.

TypeEmerging player
Description

Know Labs is developing a non-invasive glucose monitor using radiofrequency/bioimpedance spectroscopy in a wrist-worn form factor. It is the closest emerging competitor to Afon, pursuing a sensor approach in the same 'needle-free CGM' category.

TypeDirect peer
Description

Senseonics markets Eversense, an implantable long-term CGM (6-month sensor). It is comparable to Afon because both pursue multi-month/month-long glucose sensing versus the 10-14-day disposable model, though Eversense still requires an under-skin implant.

TypeDirect peer
Description

Abbott's FreeStyle Libre is the world's largest-selling CGM, providing real-time interstitial glucose data via a patch sensor. It is the primary incumbent Afon would displace if Glucowear achieves clinical-grade non-invasive accuracy.

TypeEmerging player
Description

Verily (Alphabet subsidiary) has historically pursued non-invasive glucose monitoring, including its now-shelved contact-lens glucose sensing program with Novartis. It is a relevant emerging competitor with deep R&D and platform integration potential (Fitbit, Pixel) versus Afon's wrist-worn sensor.

TypeBroad incumbent
Description

Ascensia (CONTOUR range) is a global BGM player serving people with diabetes. It is a comparable incumbent in blood-glucose monitoring but has no non-invasive CGM offering.

TypeBroad incumbent
Description

Roche Diabetes Care sells Accu-Chek blood glucose meters and insulin delivery systems and is a longstanding incumbent in BGM and insulin dosing. It overlaps with Afon in serving people with diabetes who monitor glucose, but its portfolio remains invasive-test and pump-based.

TypeBroad incumbent
Description

LifeScan markets OneTouch blood glucose meters and is a major BGM incumbent. While it has not launched a true CGM, it is a relevant comparable on the blood-glucose-monitoring category targeting people with diabetes.

TypeBroad incumbent
Description

Apple is widely reported to be working on non-invasive glucose monitoring for Apple Watch. Although it has not shipped a CGM, its installed base of 100M+ Watches and supplier scale make it a credible future head-to-head competitor for Glucowear in the lifestyle/non-diabetic segment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Afon Technology

Continuous Glucose Monitoring Devicesafontechnology.com

Afon Technology is a UK-based medical device company developing Glucowear™, a wrist-worn, non-invasive continuous blood glucose monitor using RF/microwave technology. Pre-revenue, it is in clinical trials ahead of a planned 2026 UK launch for people with diabetes and metabolic-health consumers.

What Afon Technology does

Afon Technology Ltd is a UK-based medical device company developing Glucowear™, a non-invasive, wrist-worn continuous blood glucose monitor. Founded by Dr Sabih Chaudhry and headquartered in Caldicot, Monmouthshire, Wales, the company has built a watch-format device that uses RF/microwave technology to analyse spectral variations in low-power radio signals reflected from the wrist to detect glucose levels, without skin penetration, needle insertion, or finger-prick calibration. The signal is transmitted via Bluetooth to a companion smartphone app for real-time display, and the device is designed for a two-year operational lifespan with minimal plastic and recyclable packaging. The underlying technology is protected by a granted patent (registered 2019) on the first real-time non-invasive blood glucose monitor.

The company is pre-commercial and is in clinical trials ahead of an anticipated UK launch in 2026. Manufacturing has been secured through a partnership with Sony UK Technology Centre announced in late 2025. Quality systems are BSI ISO 13485-certified (May 2023), and clinical evidence includes a proof-of-concept study in the Journal of Diabetes Science and Technology (April 2023, with an AI-accuracy pilot study published May 2024), ongoing NHS trials at the Joint Clinical Research Facility at Swansea University, and a real-world trial reporting approximately 75% overall accuracy with median ARD of 22% and mean ARD of 28% in Stage 2 testing.

Afon's business model centres on one-time, up-front hardware sales of the Glucowear device in the UK, with no subscription, membership, or replacement-sensor fees. The product is positioned both as a medical device for people with Type 1 and Type 2 diabetes and as a lifestyle accessory for prediabetics and metabolic-health-conscious non-diabetic consumers. To date, the company has been funded primarily through non-dilutive European Innovation Council grants (€2.5M in December 2022, €2.4M in May 2025 via Horizon Europe), a £600,000 confidential investor round in November 2022, and a $25,000 Junkosha Technology Innovator of the Year prize in April 2024; revenue has not yet been disclosed and the company is currently pre-revenue.

Afon Technology firmographics

Firmographics
Name
Afon Technology
Legal name
Afon Technology Ltd
Website
https://afontechnology.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Afon Technology is a UK-based medical device company developing Glucowear™, a wrist-worn, non-invasive continuous blood glucose monitor using RF/microwave technology. Pre-revenue, it is in clinical trials ahead of a planned 2026 UK launch for people with diabetes and metabolic-health consumers.
Ownership category
akta.pro rank

Afon Technology industry classification

Industry
Product category
Continuous Glucose Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Non-invasive glucose monitoring
  • Continuous glucose monitor
  • Wearable medical device
  • Blood glucose sensor
  • Diabetes monitoring technology

Where Afon Technology is headquartered

Location

Headquarters

HQ city
Caldicot
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Afon Technology business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Hardware Device Sales: Afon Technology sells Glucowear, a wearable medical device. The company plans to sell the device in the UK market with plans to begin selling in 2026. The device is described as having no additional running costs or membership fees, just an up-front purchase cost.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goSingle device purchase model with no ongoing subscription fees

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Afon Technology product offering

Product offering

Core offering

Afon Technology develops Glucowear™, a wrist-worn wearable medical device that uses proprietary RF/microwave-based dial resonating sensor technology to continuously and non-invasively measure blood glucose levels in real time through spectral analysis of signals reflected from the wrist, without skin penetration or finger pricks. The device transmits readings via Bluetooth to a companion smartphone application, is designed for a two-year reusable lifespan, and is manufactured by Sony UK Technology Centre ahead of an anticipated 2026 UK commercial launch following NHS-backed clinical trials.

Product overview

Afon Technology offers a single unified product, Glucowear™, which is the world's first non-invasive, real-time continuous blood glucose monitor. This wrist-worn device represents a paradigm shift from traditional invasive CGM systems that require needle sensors inserted under the skin. Glucowear uses ultra-low power microwave/RF signals to detect glucose levels and transmits data via Bluetooth to a companion smartphone app for real-time display. The device targets people with diabetes and prediabetes, as well as non-diabetic users interested in metabolic health monitoring. The company is currently in clinical trials ahead of an anticipated 2026 commercial launch in the UK, with manufacturing handled by Sony UK Technology Centre.

Differentiator

Problem solved

Functional benefit

Brands

  • Glucowear™: The world's first non-invasive, real-time and continuous blood glucose sensor. A wrist-worn device that uses RF/microwave technology to monitor glucose levels without penetrating the skin, connecting via Bluetooth to smart devices and apps.

Products and services

  • Glucowear™ A wrist-worn, non-invasive, real-time continuous blood glucose monitor that uses proprietary RF/microwave-based dial resonating sensor technology to detect glucose levels through spectral analysis of signals reflected from the wrist, without skin penetration. The device transmits readings via Bluetooth to a companion smartphone app, is designed for a two-year reusable lifespan, works on all skin colours, and is intended for people with Type 1 or Type 2 diabetes as well as health-conscious non-diabetics seeking metabolic health insights. Manufacturing is handled by Sony UK Technology Centre ahead of an anticipated 2026 UK commercial launch following NHS clinical trials.

Quantifiable outcome

  • ~75% overall accuracy in distinguishing between normal and elevated blood glucose levels in first real-world trial (March 2026)
  • +3 more outcomes

Companies that use Afon Technology

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Afon Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Afon Technology partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Sony UK Technology CentrecoreOEM/ Whitelabel/ Licensing Partner · 18 December 2025Afon Technology partnered with Sony UK Technology Centre to manufacture Glucowear, its non-invasive continuous glucose monitoring device. The partnership was described as a pivotal moment in Afon's history, with Sony's manufacturing capabilities being used to scale production for the 2026 commercial launch in the UK. The agreement was finalized in late 2025 following an initial announcement in October 2025.
  • Journal of Diabetes Science and TechnologyminorStrategic or Co-development Partner · 27 April 2023Afon Technology published a clinical proof-of-concept study 'Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor' in the Journal of Diabetes Science and Technology in April 2023. The paper was co-authored with researchers from multiple institutions.
  • Joint Clinical Research Facility (JCRF), Swansea UniversityminorStrategic or Co-development Partner · 1 February 2023Afon Technology is conducting clinical trials at the Joint Clinical Research Facility (JCRF) at Swansea University, where preliminary results were presented at ATTD Berlin 2023.
  • Royal Liverpool HospitalminorStrategic or Co-development PartnerDr Sabih Chaudhry worked with the Royal Liverpool Hospital in 2013 to conduct the first trials on the non-invasive blood glucose monitoring technology, which was the foundational proof-of-concept work for Afon Technology.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Afon Technology competitors and assessment

Company assessment

Direct peers

  • Dexcom: Dexcom is the dominant player in continuous glucose monitoring (GCM), with the G6/G7 sensor lines used by hundreds of thousands of people with diabetes. Afon's Glucowear competes for the same end-user (continuous, real-time glucose data) but with a non-invasive watch-form device versus Dexcom's skin-penetrating patch.
  • Senseonics (Eversense): Senseonics markets Eversense, an implantable long-term CGM (6-month sensor). It is comparable to Afon because both pursue multi-month/month-long glucose sensing versus the 10-14-day disposable model, though Eversense still requires an under-skin implant.
  • Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the world's largest-selling CGM, providing real-time interstitial glucose data via a patch sensor. It is the primary incumbent Afon would displace if Glucowear achieves clinical-grade non-invasive accuracy.

Broad incumbents

  • Medtronic Diabetes: Medtronic offers the Guardian CGM alongside its insulin pumps and closed-loop systems, targeting people with Type 1 diabetes. As a broad diabetes device incumbent it overlaps with Afon's target use case, though it does not currently address non-invasive or lifestyle segments.
  • Ascensia Diabetes Care: Ascensia (CONTOUR range) is a global BGM player serving people with diabetes. It is a comparable incumbent in blood-glucose monitoring but has no non-invasive CGM offering.
  • Roche Diabetes Care: Roche Diabetes Care sells Accu-Chek blood glucose meters and insulin delivery systems and is a longstanding incumbent in BGM and insulin dosing. It overlaps with Afon in serving people with diabetes who monitor glucose, but its portfolio remains invasive-test and pump-based.
  • LifeScan (OneTouch): LifeScan markets OneTouch blood glucose meters and is a major BGM incumbent. While it has not launched a true CGM, it is a relevant comparable on the blood-glucose-monitoring category targeting people with diabetes.
  • Apple (Health / Watch): Apple is widely reported to be working on non-invasive glucose monitoring for Apple Watch. Although it has not shipped a CGM, its installed base of 100M+ Watches and supplier scale make it a credible future head-to-head competitor for Glucowear in the lifestyle/non-diabetic segment.

Emerging players

  • Know Labs: Know Labs is developing a non-invasive glucose monitor using radiofrequency/bioimpedance spectroscopy in a wrist-worn form factor. It is the closest emerging competitor to Afon, pursuing a sensor approach in the same 'needle-free CGM' category.
  • Verily (Alphabet): Verily (Alphabet subsidiary) has historically pursued non-invasive glucose monitoring, including its now-shelved contact-lens glucose sensing program with Novartis. It is a relevant emerging competitor with deep R&D and platform integration potential (Fitbit, Pixel) versus Afon's wrist-worn sensor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Afon Technology social profiles

Digital presence

Afon Technology compliance and trust

Trust signal

Compliance1 record

Afon Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Afon Technology leadership team

Management profile

Number of profiles

Profiles11 records

Afon Technology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Afon Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Afon Technology

What does Afon Technology do?

Afon Technology develops Glucowear™, a wrist-worn wearable medical device that uses proprietary RF/microwave-based dial resonating sensor technology to continuously and non-invasively measure blood glucose levels in real time through spectral analysis of signals reflected from the wrist, without skin penetration or finger pricks. The device transmits readings via Bluetooth to a companion smartphone application, is designed for a two-year reusable lifespan, and is manufactured by Sony UK Technology Centre ahead of an anticipated 2026 UK commercial launch following NHS-backed clinical trials.

Is Afon Technology a public or private company?

Afon Technology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Afon Technology founded?

Afon Technology was founded in 2013. It employs 11 to 50 people.

Where is Afon Technology based?

Afon Technology is headquartered in Caldicot, United Kingdom, in the Europe region.

How does Afon Technology make money?

One revenue line is on record: hardware Device Sales.

Who are Afon Technology's main competitors?

Direct peers on record are Dexcom, Senseonics (Eversense) and Abbott Diabetes Care (FreeStyle Libre). Broad incumbents are Medtronic Diabetes, Ascensia Diabetes Care, Roche Diabetes Care, LifeScan (OneTouch) and Apple (Health / Watch). Emerging players are Know Labs and Verily (Alphabet).

Does Afon Technology have an API?

No public API is recorded for Afon Technology.

What industry is Afon Technology in?

Afon Technology's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips, with a secondary code of CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Med-Tech InsightsMedilink UK 2026 Healthcare Business Awards Winners & Runners Up AnnouncedMedilink UK announced its 2026 Healthcare Business Awards winners and runners up, with the national ceremony held at Victoria House, London on 9 July. Winners span start-up, digital, innovation, sustainability, partnership, academia, NHS acute, primary/social, export, and outstanding achievement categories, including CARDIOVOLT.AI, i3 SIMULATIONS, and ABINGDON HEALTH.openPR.comUnited States Non-Invasive Glucose Monitoring Devices Market Grows at 7.5% CAGR as Wearable Sensors and Needle-Free Diabetes Care Gain MomentumThe global non-invasive glucose monitoring devices market reached US$ 29.53 million in 2023 and is expected to reach US$ 60.71 million by 2033, growing at a CAGR of 7.5%, driven by rising global diabetes prevalence (affecting 537 million adults in 2023) and patient demand for pain-free needle-free monitoring technologies. Recent industry developments include Garmin's patent filing for non-invasive glycated haemoglobin estimation in smartwatches (June 2025), Afon Technology's launch of the world's first non-invasive real-time glucose sensor Glucowear (February 2025), and Know Labs' KnowU pursuing FDA clearance. North America leads the market with a valuation of US$ 13.2 million in 2024.Open Access GovernmentSony UK technology centre to manufacture Afon Technology’s revolutionary diabetes management deviceAfon Technology, a Welsh medtech company, has partnered with Sony UK Technology Centre to manufacture GlucowearTM, its non-invasive continuous glucose monitoring device, marking what the company calls a pivotal moment in its history. The device uses RF/microwave technology to measure blood sugar levels without breaking the skin, unlike conventional monitors that require sensors inserted under the skin. Afon Technology is currently putting the device through testing and trials, with plans to begin selling it in the UK.Med-Tech InsightsAfon to sign agreement with Sony UK TEC for wearable blood glucose indicatorAfon Technology Ltd is finalizing a manufacturing agreement with Sony UK TEC to produce its Glucowear device, a non-invasive wearable blood glucose indicator. The device transmits real-time glucose data via Bluetooth to a companion app, and the partnership aims to bring the product to market at scale.Healthcare NewsdeskWorld-first wearable diabetes monitor being developed with EU funding boostAfon Technology Ltd, a Welsh company based in Caldicot, has received €2.4 million in funding from the European Innovation Council through the Horizon Europe programme to develop Glucowear, a world-first wearable non-invasive blood glucose sensor. The device uses ultra-low power microwave signals to monitor blood glucose levels in real-time without penetrating the skin, potentially eliminating the need for frequent finger pricking in diabetes management. Afon Technology hopes to beat major tech companies such as Apple, Samsung and Google, which are reportedly working on similar non-invasive glucose monitoring technology but have not yet succeeded.SocialcareMore than £2m for wearable diabetes monitor being developed in WalesWelsh medical technology company Afon Technology Ltd has secured €2.4m (over £2m) in funding from Horizon Europe, the EU's flagship research programme, to accelerate development of its "Glucowear" wearable blood glucose sensor. The device uses ultra-low power microwave signals to monitor glucose levels in real-time without invasive blood testing, offering a potential alternative to traditional finger-prick methods for the 4.3 million people in the UK living with diabetes. The Welsh government is encouraging more researchers and businesses in Wales to apply to the Horizon Europe programme, which remains open until 2027 under the UK's Associate Country status.Wired-GovWorld-first wearable diabetes monitor being developed with EU funding boost | Welsh GovernmentAfon Technology Ltd, a Caldicot-based Welsh business, received over £2 million (€2.4 million) in funding from Horizon Europe to accelerate development of Glucowear, a world-first wearable non-invasive blood glucose sensor that uses ultra-low power microwave signals to monitor glucose levels in real-time. The company is pursuing what it calls the "holy grail" of glucose monitoring, aiming to eliminate the need for frequent finger pricking among diabetes patients. The Welsh Government lobbied for continued participation in the EU research programme post-Brexit, and the European Commission is running Horizon Europe through 2027.JournoLinkAfon Technology Limited (“Afon Technology”) raises £600,000Afon Technology has raised £600,000 from a confidential investor to fund the manufacturing stage of its non-invasive wearable blood glucose monitor. The company aims to commercialize this patented device, which connects via Bluetooth to smart devices, following positive results from initial trials.BusinessnewsAfon Technology Limited (“Afon Technology”) raises £600,000Afon Technology Limited has raised £600,000 from a confidential investor to advance the miniaturisation of their wearable, non-invasive blood glucose monitor, taking it into manufacturing. The device aims to empower people with diabetes through continuous glucose monitoring without conventional finger-stick methods. The company is optimistic about its technology's reliability and accuracy based on initial trials.FinSMEsAfon Technology Raises £600K in FundingAfon Technology, a med-tech startup based in Chepstow, South Wales, raised £600K in funding to accelerate growth and expand operations. The company develops a non-invasive, wearable blood glucose meter that has been tested in clinical settings and complies with major global regulatory requirements.